Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | CASR | P41180 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447439 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL30248352 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL670039 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL29447428 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL3898874 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL269429 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL269430 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL10062052 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL15092674 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 | |
| SCHEMBL26719465 | 1.00 | SLC22A1 (0.65) | SLC22A1OPRM1AOC3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791300-B2 | Process for preparing a substituted dimethyl-(3-arylbutyl)amine compound by homogeneous catalysis | GRUENENTHAL GMBH (DE) | 2014-07-29 | — | — | US | claimed |
| EP-1943211-B1 | PROCESS FOR PREPARING SUBSTITUTED DIMETHYL(3-ARYLBUTYL)AMINE COMPOUNDS BY MEANS OF HOMOGENEOUS CATALYSIS | GRUENENTHAL GMBH (DE) | 2011-08-17 | — | — | EP | claimed |
| US-20090043132-A1 | Process for Preparing a Substituted Dimethyl-(3-arylbutyl)amine Compound by Homogeneous Catalysis | GRUENENTHAL GMBH (DE) | 2009-02-12 | — | — | US | claimed |
| WO-2023209033-A1 | METHOD FOR CRYSTALLIZING TAPENTADOL INTERMEDIATE, TAPENTADOL INTERMEDIATE OF HIGH PURITY, METHOD OF MAKING TAPENTADOL AND TAPENTADOL OF HIGH PURITY | KRKA, D.D., NOVO MESTO (SI) | 2023-11-02 | — | — | WO | disclosed |
| EP-3166923-B1 | PROCESS FOR PREPARING SUBSTITUTED PHENYLALKANES | SpecGx LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-2519100-B1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | MAPI PHARMA LTD (IL) | 2017-03-15 | — | — | EP | disclosed |
| US-9556108-B2 | Process for preparing substituted phenylalkanes | MALLINCKRODT LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160009635-A1 | PROCESS FOR PREPARING SUBSTITUTED PHENYLALKANES | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2016-01-14 | — | — | US | disclosed |
| US-8791300-B2 | Process for preparing a substituted dimethyl-(3-arylbutyl)amine compound by homogeneous catalysis | GRUENENTHAL GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20090043132-A1 | Process for Preparing a Substituted Dimethyl-(3-arylbutyl)amine Compound by Homogeneous Catalysis | GRUENENTHAL GMBH (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-1943211-A1 | PROCESS FOR PREPARING SUBSTITUTED DIMETHYL(3-ARYLBUTYL)AMINE COMPOUNDS BY MEANS OF HOMOGENEOUS CATALYSIS | Grünenthal GmbH (DE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007051576-A1 | PROCESS FOR PREPARING SUBSTITUTED DIMETHYL(3-ARYLBUTYL)AMINE COMPOUNDS BY MEANS OF HOMOGENEOUS CATALYSIS | Grünenthal GmbH (DE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009635-A1 | PROCESS FOR PREPARING SUBSTITUTED PHENYLALKANES | CYP2E1, CYP1B1, CYP4B1 | SLC22A1 3503/4885OPRM1 32/4885AOC3 505/4885 |
| US-20090043132-A1 | Process for Preparing a Substituted Dimethyl-(3-arylbutyl)amine Compound by Homogeneous Catalysis | HRH3, CAT, CMA1 | SLC22A1 4631/4885OPRM1 1416/4885AOC3 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.